LACTOLOGY FOUNDATION

Cilansetron (ATC A03AE03) is a selective 5‑HT3 receptor antagonist developed for diarrhea‑predominant irritable bowel syndrome (IBS‑D), with limited, mainly investigational use and no established lactation safety profile.medpedia.framar+5

Pharmacological class and mechanism

Drugs in ATC class A03AE03 are serotonin 5‑HT3 receptor antagonists acting primarily on the enteric nervous system to modulate gastrointestinal motility and visceral sensitivity.drugs.ncats+4
Cilansetron is a high‑affinity, selective 5‑HT3 antagonist that blocks serotonin‑mediated neural and chemical signaling to 5‑HT3 receptors in the gut.pmc.ncbi.nlm.nih+6
By inhibiting 5‑HT3‑mediated neuronal activation, cilansetron slows colonic transit, improves stool consistency, reduces bowel urgency, and attenuates abdominal pain and discomfort in IBS‑D.clinicaltrialsarena+4

Indications and clinical use

Cilansetron was developed specifically for diarrhoea‑predominant IBS, aiming to provide global symptom relief (abdominal pain, stool frequency, urgency, and consistency).pubmed.ncbi.nlm.nih+5
Phase II/III trials showed superiority over placebo, with responder rates (adequate overall relief in ≥50% of weekly assessments) around 52–63% versus 37–46% for placebo, over periods up to six months.news-medical+3
Symptom improvement often occurred within the first week of therapy and was sustained during continued treatment, with benefits observed in both male and female IBS‑D patients.clinicaltrialsarena+2

Patient selection and access

In clinical development, cilansetron targeted adults with IBS‑D meeting standardized diagnostic criteria, often excluding patients with alarm features or significant structural gastrointestinal disease.drugs.ncats+3
Like other potent 5‑HT3 antagonists (e.g., alosetron), use was envisaged under prescription and with careful monitoring for serious gastrointestinal adverse events, particularly severe constipation and possible ischemic colitis.hillman.upmc+6

Adverse effects and toxicology

The most frequent adverse effect of cilansetron in trials was constipation, occurring in approximately 3–12% of subjects after six months of treatment.rxlist+4
Other commonly reported adverse effects for selective 5‑HT3 antagonists include abdominal pain, nausea, headache, fatigue, bloating, dizziness, and, less often, diarrhea or muscle spasm.hillman.upmc+2
Serious but rare toxicities described for this pharmacological class include severe constipation, bowel obstruction, ischemic colitis, and cardiac rhythm disturbances or ECG changes, warranting immediate drug discontinuation and urgent evaluation.drugbank+3

From a general toxicological standpoint, 5‑HT3 antagonists may provoke hypersensitivity reactions, including anaphylaxis, with clinical features such as facial swelling, airway compromise, rash, fever, and hemodynamic instability.hillman.upmc
Preclinical data for cilansetron indicate potent, selective 5‑HT3 blockade without major off‑target toxicity at therapeutic exposures, but long‑term safety concerns, analogous to those seen with alosetron, limited regulatory progression.openaccessjournals+4

Contraindications and precautions

Cilansetron should not be used in patients with known hypersensitivity to the active substance or excipients.medpedia.framar+2
Given class experience, cilansetron is relatively contraindicated or requires extreme caution in patients with a history of chronic constipation, intestinal obstruction, ischemic colitis, inflammatory bowel disease, or severe hepatic impairment.rxlist+4
Precautions include monitoring bowel habit changes, prompt evaluation of new or worsening abdominal pain, rectal bleeding, or signs of colitis, and discontinuation if severe constipation or ischemic colitis is suspected.drugbank+3

Use in pregnancy and lactation

Specific human data on cilansetron use during pregnancy are very limited; extrapolation from the 5‑HT3 antagonist class suggests low teratogenic risk but does not substitute for drug‑specific evidence.medsafe+2
For breastfeeding, there are no published pharmacokinetic studies or clinical case series describing cilansetron transfer into human milk or effects in breastfed infants.milkygoodness+3

Lactation risk assessment (class‑based)

General lactation guidance indicates that most medicines excreted into breast milk at <10% of the maternal weight‑adjusted dose are considered compatible with breastfeeding, provided the infant is full‑term and healthy.mayoclinic+1
5‑HT3 antagonists used as antiemetics (e.g., ondansetron) are often considered acceptable during breastfeeding when clinically indicated, although data remain incomplete and decisions are individualized.medsafe+2

For cilansetron specifically:

·        Lack of human lactation data means its safety in breastfeeding cannot be assured; by default it should be avoided or used only when potential maternal benefit clearly outweighs theoretical infant risk.milkygoodness+3

·        If use is unavoidable, risk‑minimizing strategies include using the lowest effective dose for the shortest duration and timing doses immediately after breastfeeding to reduce peak infant exposure.mayoclinic+1

·        Clinical monitoring of the breastfed infant should focus on gastrointestinal symptoms (constipation, altered stool pattern, feeding difficulties) and general wellbeing.medsafe+2

Alternative agents with better lactation data should be preferred for IBS‑D in breastfeeding women, and consultation with a specialist service (e.g., LactMed, medicines information centres) is strongly recommended before off‑label use.milkygoodness+2

Summary for web monograph

Cilansetron (ATC A03AE03) is a high‑affinity, selective 5‑HT3 receptor antagonist developed for diarrhea‑predominant irritable bowel syndrome, acting by modulation of serotonergic signaling in the gut to slow transit and reduce visceral hypersensitivity.pmc.ncbi.nlm.nih+7
Clinical trials demonstrated meaningful improvements in global IBS‑D symptoms versus placebo, with relatively frequent constipation and rare but serious class‑related gastrointestinal and cardiac adverse events, warranting careful patient selection and monitoring.pubmed.ncbi.nlm.nih+6
Due to the absence of specific pregnancy and lactation data, cilansetron is not routinely recommended for breastfeeding women; decisions should be individualized, favouring better‑studied alternatives and adhering to general toxicology‑lactology principles for minimizing infant exposure.mayoclinic+3